Joint bleeding, a key complication contributing to musculoskeletal deterioration, can be largely prevented through prophylactic administration of current hemophilia treatments, including plasma-derived FVIII concentrates, standard recombinant FVIII (rFVIII), and extended half-life rFVIII. The gene discussed is F8; the disease is hemophilia.